Real World Evidence

(342) Factors affecting autologous stem cell transplant access in multiple myeloma patients at a comprehensive cancer center

(343) Research Topics Addressed in Observational Claims-based Studies in Pharmacy

(344) Disruption and adaptation in inflammatory bowel disease: Impact of the COVID-19 pandemic on treatment patterns, healthcare utilization, and vaccination in the United States

(345) Cost-Effectiveness Analysis of Lenacapavir Compared to Cabotegravir and Generic Oral FTC/TDF for HIV Pre-Exposure Prophylaxis among Cis-gender Women in the United States

(346) Real-world healthcare resource utilization and economic burden associated with idiopathic pulmonary fibrosis in commercially insured and Medicare Advantage Populations in the United States

(347) Estimation of the minimal clinically important difference (MCID) and longitudinal change in the tardive dyskinesia impact scale (TDIS), a validated, tardive dyskinesia-specific, patient-reported outcome measure

(348) Real-world healthcare resource utilization and economic burden associated with progressive pulmonary fibrosis in commercially insured and Medicare Advantage Populations in the United States

(349) AUVI-Q (epinephrine, USP) vs. other epinephrine auto-injector prescription was associated with reduced inpatient hospitalizations for anaphylaxis in a US retrospective commercial claims analysis

(350) Real-world Incremental Economic Burden of Fatigue among Patients with Obstructive Sleep Apnea in the Medicare Fee-for-Service Population

(351) The Economic Burden of Narcolepsy in the United States: Matched Analysis of National Health and Wellness Survey Data

(352) Transportability to the EU Population of the Efficacy of Belumosudil Versus Best Available Therapy for the Treatment of Chronic Graft-Versus-Host Disease

(353) Real world assessment of manic events among patients with bipolar I disorder treated with cariprazine versus other atypical antipsychotics

(354) Healthcare resource utilization following cariprazine initiation among medicare beneficiaries with bipolar I disorder

(355) Real-world switch rates of injectable migraine preventive therapies in patients with chronic migraine

(356) Evaluation of unmet needs and quality-of-care indicators among patients with migraine in the United States: 2021–2022

(358) Increased health care resource utilization in children and adolescents with Tourette syndrome treated with dopamine D2 receptor antagonists/partial agonists: an electronic health records database analysis

(359) Healthcare Resource Utilization in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Study Results

(360) Real-World Clinical Outcomes and Disease Management Costs among High-Risk Non-Muscle Invasive Bladder Cancer Patients Treated with Bacillus Calmette-Guérin: A SEER-Medicare Analysis

(361) Real-world demographics, clinical characteristics, and medication utilization in biopsy-confirmed primary C3 glomerulopathy: A 20-year single-center EHR cohort study

(362) Real-world characteristics and treatment patterns of patients with major depressive disorder initiating dextromethorphan-bupropion extended-release tablets, cariprazine, brexpiprazole, or esketamine

(363) Real-world insights on tardive dyskinesia: a claims-based analysis of demographics and healthcare utilization

(364) Real-world healthcare utilization and costs associated with using dextromethorphan-bupropion extended-release tablets versus branded comparators for the treatment of major depressive disorder

(365) Mapping the Cirrhosis Journey: Cirrhosis Etiologies and Rates, Timing, and Cost of Complications in a US claims database

(366) Healthcare costs for patients with major depressive disorder initiating dextromethorphan-bupropion extended-release tablets as a first or subsequent line of treatment

(367) Healthcare costs associated with timely diagnosis of mild cognitive impairment and Alzheimer's Disease

(368) Comparisons of pharmacy-dispensed medications in the 2022 Medical Expenditure Panel Survey and the Healthcare Integrated Research Database

(369) Burden of anti-seizure medication titration on healthcare resource utilization and costs among patients with focal onset seizures: A physician panel-based chart review

(370) Triptans, opioids, and rescue medications use among patients with migraines Prescribed CGRP for Migraine Prophylaxis

(371) Clinical and economic burden of patients with Hunter Syndrome in the United States: a retrospective cohort study

(372) A retrospective cohort study examining the real-world disease progression, HCRU, and costs among patients with T2D with newly diagnosed CKD stage III or IV with and without finerenone use

(373) Real-World Visual Outcomes by Healthcare Insurance with Prescription Digital Treatment for Amblyopia: PUPiL Registry Analysis

(374) Data linkage and tokenization in action: A systematic review of North American clinical trials utilizing linkage to real world data

(375) Socioeconomic disparities in healthcare resource utilization and costs among Medicare Fee-for-Service beneficiaries with progressive pulmonary fibrosis

(376) Real-world persistence of first-line advanced therapies in patients with psoriatic arthritis

(377) Healthcare Costs and Resource Utilization in Medicaid-insured People with Overweight or Obesity and Knee Osteoarthritis in the United States: A Retrospective Database Study

(378) Use of Health Services by People Living with Alexander's Disease

(379) Antipsychotic medication utilization and treatment patterns among patients with schizophrenia: A real-world evidence study

(380) Treatment patterns among patients with Neuromyelitis Optica Spectrum Disorder (NMOSD): A real-world evidence study

(381) Cost-effectiveness of VOWST (fecal microbiota spores, live-brpk; VOS, formerly SER-109) for Prevention of Recurrent Clostridioides difficile Infection in the United States (US)

(382) A claims-based analysis of the real-world economic burden of illness in patients with Sjögren’s disease in the United States

(383) Healthcare burden of eosinophilic esophagitis by disease severity: a retrospective cohort study of US health insurance claims data

(384) Economic burden among patients with high-risk and low-to-intermediate-risk localized prostate cancer receiving radical prostatectomy in the United States

(385) Real-world treatment history and economic outcomes of CD38 antibody-based regimens in relapsed/refractory multiple myeloma in the United States

(386) Do claims data support use of CPT category II codes for real-world evidence clinical outcomes?

(387) A Propensity Score-Matched Analysis of Healthcare Utilization and Cost in Medicaid Beneficiaries with Epilepsy

(388) Cost savings from pharmacist-led deprescribing in older adults: A real-world economic perspective

(389) Healthcare Resource Utilization and Costs in Patients with Metabolic Dysfunction Associated Steatohepatitis: A Comparison Between Patients with Diagnosed MASH, Probable MASH, and Without MASH

(390) An Analysis of solid tumor oncology patients’ respiratory vaccination rates in accordance with ASCO guidelines

(391) Trends in Opioid Abuse Disorder Diagnoses, Hospitalizations, and Receipt of Guideline-Recommended Treatment After Hospitalization by Insurance Type, Sex, and Age (2021-2024)

(392) Impact of dupilumab on healthcare resource utilization and its treatment patterns in patients with atopic dermatitis and comorbid asthma: A non-interventional study utilizing a U.S. claims database

(393) Incremental Healthcare Costs of Psychoses and Agitation/Aggression among Medicare Beneficiaries with Alzheimer’s Disease

(394) Improved outcomes in patients with multiple sclerosis initiating cladribine tablets compared with those denied health insurance coverage in the United States

(395) Impact on accountable care organization diabetes population; health plan pharmacist value-based care engagement

(396) Long-term Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Costs Among People with Cystic Fibrosis Aged ≥6 Years in the US: A Retrospective Analysis of Commercial Claims in the Forsyth HealthSM Proprietary Database

(399) Real-World Uptake of Respiratory Syncytial Virus Vaccination Among Older Adults on Immunosuppressive Therapies

(400) Patterns of Postpartum Contraceptive Use within an Academic Health Care Setting: A Descriptive Study